Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY), the leading RNAi therapeutics company, today announced that it will present new clinical and real-world data across its transthyretin-mediated amyloidosis (ATTR) and hypertension programs at the European Society of Cardiology (ESC) Congress 2026, taking place August 28-31, 2026, in Munich, Germany. These presentations add to the existing and growing body of evidence demonstrating strength in RNAi-powered transthyretin (TTR) silencing with AMVUTTRA® (vutrisiran) and underscore the potential of zilebesiran as an innovative treatment approach for hypertension, the leading preventable risk factor for cardiovascular disease (CVD) worldwide.